Drug Trial Radar · NCT03959553
GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)
Last checked: Nov 19, 2026Latest source record: Mar 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 1, 2019
Primary completion
Aug 31, 2021
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for moderate Alzheimer's disease (AD). GV1001 has been shown to inhibit neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 has been shown to improve cognitive function and memory, as well as significantly reduce the amount of amyloid beta and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD.
Conditions
- Moderate Alzheimer's Disease
Interventions
GV1001Drug
Lyophilized peptide from hTERT
Normal salineDrug
0.9% normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog)Time frame: Week 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.